Gapping up
News:
- RNLX +9% (signed a contract with BlueCross and BlueShield of Texas to expand insurance coverage of KidneyIntelX in the state of Texas)
- HPK +6.6% (CEO bought 500,000 shares)
- ATEX +5.9% (authorized new $250 mln share repurchase program)
- FFIE +5.2% (Announces Management Stock Purchase Plan)
- SGEN +3.9% (Seagen and Merck (MRK) report PADCEV and KEYTRUDA significantly improve Overall Survival and Progression-Free Survival in patients with previously untreated advanced bladder cancer in Pivotal Phase 3 EV-302 Trial)
- ATS +3.7% (to acquire Avidity Science for $195 mln)
- ASLN +3% (Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress)
- ZYME +2.8% (ZYME and BGNE terminate collaboration agreement for zanidatamab zovodotin)
- AZN +2.8% (reports first Phase III results for datopotamab deruxtecan; Plans for global regulatory submissions underway)
- DDD +2.4% (CFO to step down)
- EBAY +2% (issues statement regarding Adevinta comments)
- PRPL +1.9% (names new CFO)
- ATVI +1.8% (UK CMA provides update on approval Microsoft (MSFT)/ Activision Blizzard)
- X +1.2% (Canada's Stelco weighs bid for US Steel according to Bloomberg)
- AMZN +1% (provides Prime Video update - starting in early 2024 Prime Video shows and movies will include limited advertisements)
- MAS +0.7% (names new CFO)
Analyst comments:
- CDE +4.7% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- YUMC +2.7% (upgraded to Buy from Hold at Jefferies)
- W +2.4% (upgraded to Mkt Perform from Underperform at Bernstein)
- RL +0.8% (initiated with an Outperform at Raymond James)